What's new in atopic eczema? An analysis of systematic reviews published in 2019. Part 2: treatment. (1st October 2021)

• Record Type: Journal Article
• Authors: Marrouche, N.; Lancaster, N.; Grindlay, D. J. C.; Rogers, N. K.; Olabi, B.
• Is Part Of: Clinical and experimental dermatology. Volume 46:Number 7(2021)
• Page Start: 1211
• Page End: 1215
• Publication Date: 2021-10-01
• Subjects: Skin -- Diseases -- Periodicals; 616.5
• DOI: 10.1111/ced.14775
• Languages: English
• ISSNs: 0307-6938

Abstract

Summary: This review forms part of a series of annual evidence updates on atopic eczema (AE), and provides a summary of key findings from systematic reviews (SRs) published or indexed in 2019 related to AE treatment. Several SRs assessed the efficacy of topical corticosteroids (TCS), topical calcineurin inhibitors, topical phosphodiesterase‐4 inhibitors and topical Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway inhibitors. However, there is a lack of good‐quality trials comparing topical treatment agents with TCS, which remain the standard of care for patients with AE. Most of the included trials lack meaningful comparisons as they used vehicle as a comparator. There is also lack of harmonization of outcome measures for AE across studies. Large, well‐designed RCTs are needed to further determine whether any specific emollients offer superior benefit. There is evidence highlighting limited benefit of oral H1 antihistamines as 'add‐on' therapy to topical treatment of eczema. Mycophenolate mofetil may have a role in patients with refractory AE. Among biologic therapies, most of the efficacy data relate to dupilumab. Furthermore, there is growing evidence for the efficacy and safety of systemic JAK/STAT pathway inhibitors, but the existing data are of low quality. Abstract : Click here for the corresponding questions to this CME article.